At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 129 enrolled
Drug / intervention
Duvelisibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma
In Brief
A Phase 2 clinical trial evaluating Duvelisib for Indolent Non-Hodgkin Lymphoma. Completed, enrolled 129 participants across 69 sites in 12 countries.
Detailed Summary
This was a Phase 2 clinical trial to evaluate the safety and efficacy of duvelisib as a monotherapy in participants with indolent non-Hodgkin lymphoma (iNHL) (follicular lymphoma \[FL\], marginal zone lymphoma, or small lymphocytic lymphoma) that was refractory to rituximab and to either chemotherapy or radioimmunotherapy (RIT).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIndolent Non-Hodgkin Lymphoma
CountriesBelarus, Belgium, Bulgaria, Canada, Czechia, France, Georgia, Hungary, Italy, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJun 2013
First PostedJun 2013
Primary CompletionNov 2020
TodayJul 2026
First PostedJun 20, 2013
Enrollment StartJun 17, 2013
Primary CompletionNov 18, 2020
TodayJul 2, 2026
Enrollment to primary: 7.4 yearsPosted 13.0 years ago
Interventions
Duvelisibdrug
Phosphoinositide-3-kinase (PI3K) inhibitor